Standout Papers
Immediate Impact
7 from Science/Nature 85 standout
Citing Papers
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024 Standout
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
2024 Standout
Works of Haoda Fu being referenced
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies
2015
The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
2013 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Haoda Fu | 525 | 462 | 255 | 704 | 76 | 2.0k | |
| Lilly Q. Yue | 587 | 242 | 517 | 254 | 42 | 2.2k | |
| Vikram Sinha | 231 | 457 | 154 | 463 | 74 | 2.3k | |
| Christoffer W. Tornøe | 226 | 885 | 118 | 587 | 28 | 2.2k | |
| Sanjib Basu | 317 | 219 | 69 | 481 | 158 | 2.4k | |
| William A. Bartlett | 225 | 459 | 56 | 259 | 69 | 2.1k | |
| Norbert Benda | 203 | 214 | 106 | 178 | 82 | 1.8k | |
| Masahiko Gosho | 165 | 561 | 104 | 264 | 172 | 2.3k | |
| Bart A. Ploeger | 142 | 278 | 56 | 621 | 67 | 2.3k | |
| Bruno Flamion | 86 | 122 | 338 | 634 | 69 | 2.2k | |
| Olli Saarela | 215 | 129 | 92 | 301 | 86 | 1.8k |
All Works
Login with ORCID to disown or claim papers
Loading papers...